Skip to main content
Clinical Trials/NCT01571622
NCT01571622CompletedNot Applicable

Effect of Whey Protein Concentrate on Postprandial Glycemic Insulin, Active and Intact GLP-1and GIP, and DPP-4 Response in Type 2 Diabetic Patients

Tel Aviv University2 sites in 1 country19 target enrollmentStarted: April 2012Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
19
Locations
2
Primary Endpoint
Glucose response

Study Overview

Brief Summary

The aim of the present study is to examine the therapeutic effect of whey protein concentrate (WPC 80) in adult subjects with in type 2 diabetes. Whey protein will be administered before breakfast and its effects on posprandial glucose, insulin, c-peptide, intact and total GIP and GLP-1, and DPP-4 plasma levels will be assessed.

Detailed Description

Milk and dairy product consumption has been associated with lower risk of metabolic disorders and cardiovascular diseases (1). A population-based prospective study (CARDIA) revealed that dairy consumption was inversely associated with the prevalence of all components of the insulin resistance syndrome (IRS) in overweight individuals (2).

Whey accounts for about 20% of whole milk protein, while casein accounts for the rest. Whey protein is a source of bioactive components and branch chained amino acids (BCAAs) which could play a further role in the control of food intake and management of glucose metabolism, obesity and diabetes (1,3,4).

Whey protein appears to have insulinotropic and glucose lowering properties in healthy adults (6-9), and also in individuals with type 2 diabetes (10,11). The magnitude of postprandial blood glucose reduction following ingestion of whey protein is comparable to that observed with pharmaceutical interventions such as sulfonylureas (12) or nateglinide (13). These findings imply an important role for whey protein in the management of type 2 diabetes (10).

Whey protein seems to induce insulinotropic/β-cell-stimulating and glucose lowering effects via bioactive peptides generated during gastrointestinal digestion of BCAAs contained in β-lactoglobulin, the major whey protein (14).

These bioactive peptides stimulate the release of several gut hormones, especially the incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which potentiate insulin secretion from β-cells and are also associated with the control of food intake (9, 15-17). Increased plasma levels of GIP and GLP-1 have been reported following whey ingestion in patients with type 2 diabetes (10). The stimulatory effect of whey protein on GLP-1 is especially important since it has been shown that postprandial GLP-1 secretion is reduced in type 2 diabetes (18).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Type 2 diabetic patients
  • Duration of diabetes: 1-10 years
  • Subjects ≥ 40 and ≤70 years of age
  • Metformin therapy and all oral antidiabetic medication will be allowed
  • Overweight or obese (BMI: 25 to 35 kg/m2)
  • Normal liver and kidney function
  • Normal thyroid function
  • Read and understood the informed consent form and signed it voluntarily

Exclusion Criteria

  • Liver, heart, kidney, lung, infectious, neurological, psychiatric, immunological or neoplastic diseases.
  • Type 1 or insulin treated diabetes.
  • Pregnancy or lactation
  • Illicit drug abuse or alcoholism
  • Subject treated with insulin or treatment with degradation-resistant GLP-1R agonists (Exendin-4) or similar and DPP4 inhibitors (Januvia)
  • Subjects taking anoretic drugs
  • Subjects on steroid treatment
  • Subjects known by the principal investigator to be unable to cooperate for any reason.
  • Known hypersensitivity to milk components
  • Subjects after bariatric surgery.

Arms & Interventions

Water before breakfast

Placebo Comparator

Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water

Intervention: Whey before Breakfast (Dietary Supplement)

Water before breakfast

Placebo Comparator

Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water

Intervention: Water before breakfast (Dietary Supplement)

Whey before breakfast

Experimental

Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\

Intervention: Whey before Breakfast (Dietary Supplement)

Whey before breakfast

Experimental

Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\

Intervention: Water before breakfast (Dietary Supplement)

Outcomes

Primary Outcomes

Glucose response

Time Frame: During 4 hours meal challenge

In all 25 subjects, the effects of whey protein ingestion posprandial glucose, will be measured. Thirty minutes prior to breakfast, subjects will preloaded with one of 2 alternatives: 1. (250 ml) water 2. Whey Protein Concentrate (WPC 80 %), 45 gr dissolved in 250 ml of water

Secondary Outcomes

  • Insulin GLP-1, GIP and DPP4(During 4 hours after meal challange)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Daniela Jakubowicz

Professor Daniela Jakubowicz MD

Tel Aviv University

Study Sites (2)

Loading locations...

Similar Trials

Whey Protein on Posprandial Glucose,... | Clinical Trial